HEPS vs LGIH

The company exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. While revenue growth remains strong at 36.9% YoY, this has failed to translate into profitability, as evidenced by a catastrophic ROE of -213.73% and a consistent track record of missing earnings estimates. Liquidity is a primary concern with a Quick Ratio of 0.59 and a Current Ratio below 1.0, suggesting an inability to meet short-term obligations. Despite a positive analyst target price, the deterministic data points to a high-risk profile with significant insolvency concerns.

LGIH exhibits severe fundamental deterioration, highlighted by a weak Piotroski F-Score of 2/9 and a catastrophic YoY earnings decline of 65.10%. While the Graham Number ($79.76) suggests a deep value play based on assets, the growth-based intrinsic value ($21.84) and a 0/100 technical trend indicate the market is pricing in a structural decline. The disconnect between the low P/B ratio (0.44) and the collapsing profitability suggests a value trap. Bearish insider activity from the CEO, CFO, and President further reinforces a negative outlook.